TY - JOUR
T1 - Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide
AU - Wu, Chung Ze
AU - Pei, Dee
AU - Hsieh, An-Tsz
AU - Wang, Kun
AU - Lin, Jiunn Diann
AU - Lee, Li Hsiu
AU - Chu, Yi Min
AU - Hsiao, Fone Ching
AU - Pei, Chun
AU - Hsia, Te Lin
PY - 2010/3
Y1 - 2010/3
N2 - The traditional sulfonylureas with long half-lives have sustained stimulatory effects on insulin secretion compared to the short-acting insulin secretagogue. In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide. The design of study was randomizedcrossover. We enrolled 20 patients with new-onset type 2 diabetes (mean age, 49.3 years). Totally three FSIGTs were performed, one before and one after each of the two treatment periods as aforementioned. No significant differences in fasting plasma glucose, insulin, body mass index, blood pressure, glycated hemoglobin, or lipids were noted between the two treatments. After the repaglinide treatment, higher AIRg, lower IS, and lower SG were noted, but they did not reach statistical significance. The disposal index (DI) was also not significantly different between the two treatments. In conclusion, since non-significantly higher DI, AIRg, lower IS and SG were noted after repaglinide treatment, it might be a better treatment for diabetes, relative to gliclazide.
AB - The traditional sulfonylureas with long half-lives have sustained stimulatory effects on insulin secretion compared to the short-acting insulin secretagogue. In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide. The design of study was randomizedcrossover. We enrolled 20 patients with new-onset type 2 diabetes (mean age, 49.3 years). Totally three FSIGTs were performed, one before and one after each of the two treatment periods as aforementioned. No significant differences in fasting plasma glucose, insulin, body mass index, blood pressure, glycated hemoglobin, or lipids were noted between the two treatments. After the repaglinide treatment, higher AIRg, lower IS, and lower SG were noted, but they did not reach statistical significance. The disposal index (DI) was also not significantly different between the two treatments. In conclusion, since non-significantly higher DI, AIRg, lower IS and SG were noted after repaglinide treatment, it might be a better treatment for diabetes, relative to gliclazide.
KW - Disposal index
KW - Frequently sampled intravenous glucose tolerance test
KW - Gliclazide
KW - Insulin sensitivity
KW - Repaglinide
UR - http://www.scopus.com/inward/record.url?scp=77953634464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953634464&partnerID=8YFLogxK
U2 - 10.1007/s12272-010-0310-6
DO - 10.1007/s12272-010-0310-6
M3 - Article
C2 - 20361306
AN - SCOPUS:77953634464
SN - 0253-6269
VL - 33
SP - 411
EP - 416
JO - Archives of Pharmacal Research
JF - Archives of Pharmacal Research
IS - 3
ER -